Computational drug discovery of an inhibitor of APOBEC3B as a treatment for epithelial cancers.
APOBEC3B
De novo drug design
cancer
molecular dynamics
virtual screening
Journal
Journal of biomolecular structure & dynamics
ISSN: 1538-0254
Titre abrégé: J Biomol Struct Dyn
Pays: England
ID NLM: 8404176
Informations de publication
Date de publication:
18 Dec 2023
18 Dec 2023
Historique:
medline:
18
12
2023
pubmed:
18
12
2023
entrez:
18
12
2023
Statut:
aheadofprint
Résumé
Cancer is one of the leading causes of death in the U.S., and tumorous cancers such as cervical, lung, breast, and ovarian cancers are the most common types. APOBEC3B is a nonessential cytidine deaminase found in humans and theorized to defend against viral infection. However, overexpression of APOBEC3B is linked to cancer in humans, which makes APOBEC3B a potential cancer treatment target through competitive inhibition for several tumorous cancers. Computational studies can help reveal a small molecule inhibitor using high-throughput virtual screening of millions of candidates with relatively little cost. This study aims to narrow the field of potential APOBEC3B inhibition candidates for future
Identifiants
pubmed: 38109103
doi: 10.1080/07391102.2023.2293269
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM